Skip to main content
SpringerLink
Log in

Docetaxel: a new second-line agent for the treatment of metastatic breast cancer

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996 Jun; 51(6): 1075–92

    Article  PubMed  CAS  Google Scholar 

  2. Schellens JHM, Pronk LC, Verweij J. Emerging drug treatments for solid tumours. Drugs 1996 Jan; 51(1): 45–72

    Article  PubMed  CAS  Google Scholar 

  3. APP guide update. Taxotere. Aust J Pharm 1996 Jul; 77: 760–4

    Google Scholar 

  4. Paclitaxel: a promising addition to the antineoplastic armamentarium. Drug Ther Perspect 1995 Feb 20; 5(3): 1–5

    Google Scholar 

  5. RPR’s Taxotere approved in US. Scrip 1996 May 24; (2131): 19

  6. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994; 48(5): 794–847

    Article  PubMed  CAS  Google Scholar 

  7. British National Formulary No. 31. London: The Pharmaceutical Press, 1996 Mar: 348–59

  8. 1995 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1995

  9. Goa KL, Faulds D. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging 1994; 5(3): 200–34

    Article  PubMed  CAS  Google Scholar 

  10. Martindale. The Extra Pharmacopoeia, 30th ed. London: The Pharmaceutical Press, 1993: 494–5

  11. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995 Feb; 13: 314–22

    PubMed  CAS  Google Scholar 

  12. Hudis CA, Seidman AD, Crown JPA, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996 Jan; 14(1): 58–65

    PubMed  CAS  Google Scholar 

  13. Ravdin PM, Burris III HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracyline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995 Dec; 13(12): 2879–85

    PubMed  CAS  Google Scholar 

  14. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant breast cancer. J Clin Oncol 1995 Dec; 13(12): 2886–94

    PubMed  CAS  Google Scholar 

  15. ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere®) in second line treatment with chemotherapy for advanced breast cancer: a study of the EORTC Early Clinical Trials group. Ann Oncol 1994 Jul; 5: 527–32

    PubMed  Google Scholar 

  16. Gruia G, Misset JL, Giachetti S, et al. A phase I-II study of Taxotere (TXTR) in combination with adriamycin (AD) as first line chemotherapy (CT) in patients with metastatic breast cancer [abstract no. 258]. Proc Am Soc Clin Oncol 1995; 14: 140

    Google Scholar 

  17. Burris III HA, Fields S, Peacock N. Docetaxel (taxotere) in combination: a step forward. Semin Oncol 1995 Dec; 22 (Suppl. 13): 35–40

    PubMed  CAS  Google Scholar 

  18. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995 Oct; 13: 23–55

    Google Scholar 

  19. Ravdin PM, Valero V. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol 1995 Apr; 22 (2 Suppl. 4): 17–21

    PubMed  CAS  Google Scholar 

  20. Capri G, Tarenzi E, Fulfaro F, et al. The role of taxanes in the treatment of breast cancer. Semin Oncol 1996 Feb; 23 (1 Suppl. 2): 68–75

    PubMed  CAS  Google Scholar 

  21. Fitz-Gerald J. Modelling the cost-utility of breast cancer treatment [meeting report]. Inpharma 1996 Feb 17; (1024): 3–4

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Docetaxel: a new second-line agent for the treatment of metastatic breast cancer. Drugs Ther. Perspect 8, 1–6 (1996). https://doi.org/10.2165/00042310-199608050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199608050-00001

Keywords

Search

Navigation